Page 5 - பதிவு அறிக்கைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Purple Biotech : NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors (Form 6-K)

Message : Required fields NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recu

United statesSouth koreaGil efronBertrandc liangMegan humphreysAlberto bessudoChuck padalaExchange commissionCompany contactPurple biotech ltdCalifornia cancer associates for research excellenceDrug administrationBristol myers squibbCoeptis pharmaceuticalsMinimal adverse eventsInitial clinical data

Lankan Authorities Begin Probe in Cargo Vessel Fire Accident; to Record Statements of Ship Officials

The Criminal Investigation Department of the Sri Lankan police said while the Indian official is the deputy chief engineer of the ship, the two Russians are the captain and chief engineer respectively.

Sri lankaSri lankanKanchana wijesekeraAjith rohanaDarshani lahandapuraSri lanka navySri lankan navyInvestigation department of the sri lankanMarine environment protection authorityLankan authorities begin probeCargo vessel fire accidentRecord statementsAuthorities begin probeShip officialsColombo portIndian coast guard

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaTel avivGil efronEric rowinskySuzana nahum zilberbergChuck padalaCompany contactTeva pharmaceuticals industriesDrug administrationNextferm technologies ltdAsian international executive programExchange commissionPurple biotech ltdHuman xtention ltdTel aviv stock exchangeBristol myers squibb

Form 6-K PURPLE BIOTECH LTD For: May 19

Form 6-K PURPLE BIOTECH LTD For: May 19
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaTel avivGil efronEric rowinskySuzana nahum zilberbergChuck padalaExchange commission onCompany contactAsian international executive programPurple biotech ltdBristol myers squibbTel aviv stock exchangeCoeptis pharmaceuticalsTeva pharmaceuticals industriesDrug administration

CreditRiskMonitor Announces First Quarter Results

CreditRiskMonitor Announces First Quarter Results ACCESSWIRE 15 May 2021, 06:05 GMT+10 VALLEY COTTAGE, NY / ACCESSWIRE / May 14, 2021 / CreditRiskMonitor (OTCQX:CRMZ) reported that revenues for the quarter ended March 31, 2021 increased to $4.13 million up 11% from $3.71 million in 2020. The Company reported a reduction in operating expenses of approximately $102,600 or 2.5% as compared to 2020, primarily driven by a revised methodology of accruing commissions implemented in December 2020. The Company reported a pre-tax income of approximately $243,000 as compared to pre-tax loss of approximately $264,200 in the prior year. Mike Flum, President & COO, said, We continue to reinvest in our service with new product development, additional data acquisition, and employee retention. We remain committed to enhancing the value proposition of our services and expanding our staff to support the financial risk analysis needs of our customer base. We continue to press forward with the devel

Mike flumExchange commissionCompany registration statements or securitiesPrivate securities litigation reform actRegistration statementsUnited states wire groupபரிமாற்றம் தரகுநிறுவனம் பதிவு அறிக்கைகள் அல்லது பத்திரங்கள்ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம்பதிவு அறிக்கைகள்ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு